生技產業分析

TEL:(02) 2767-0716 FAX:(02)2768-6560 www.taipharma.com.tw [email protected]

innovation in industry)

TaiPharma Patent Attorney & Attorney at Law, 2005

(innovation)


Water Power (1789-1845) Railway (1845-1900) Electricity Chemicals Internal combustion engine(1900-1950) Aviation (1950-2000) Software Digital networks Biotech (1990-.)


Something In The AirIPRIntellectual Property Right Incubation Center Transfer Center Licensing Company


IPRPatent Trade Mark Copyright Trade Secret


(Patent tree) (ross licensing)


Freedom-To-Practice Opinion Litigation Risk Analysis Infringement Opinion




-- -- TaiPharma Patent Attorney & Attorney at Law, 2005

IPCTaiPharma Patent Attorney & Attorney at Law, 2005

- - - - - TaiPharma Patent Attorney & Attorney at Law, 2005

250

200 150 100 50 0 1976 1980 1984 1988 1992 1996 2000 TaiPharma Patent Attorney & Attorney at Law, 2005

500 450 400 350 300 250 200 150 100 50 0 0 1982 1992 20 50 100 150 200 225 1995 1996 1998 2002 2001



(/) TaiPharma Patent Attorney & Attorney at Law, 2005

() - - -



IPC ()IPC-- (Section)(Class)(Subclass) (Group)(Subgroup): A.61.K.37/00, 7/66

IPC--

IPC--

IPC IPC IPCTaiPharma Patent Attorney & Attorney at Law, 2005

-- -- IPC --

/ / TaiPharma Patent Attorney & Attorney at Law, 2005

-----


/ TaiPharma Patent Attorney & Attorney at Law, 2005


STEM CELL 5,340,740 5,786,323 5,885,962 6,162,467 ..

.. TaiPharma Patent Attorney & Attorney at Law, 2005

(claim) TaiPharma Patent Attorney & Attorney at Law, 2005


95% 40%60% vs -- --


(Patentability Search)

(Documentary Search)

(Infringement Search)

(Cancellation Search) TaiPharma Patent Attorney & Attorney at Law, 2005


1. Key Word 2. Index: IPCUS Class 3. Data Mining 4. : TaiPharma Patent Attorney & Attorney at Law, 2005

IPC.htm -01.htm -2.htm UPCinterferon Patent Classification Home Page Internet.htm index_jsp-1.htm Class Definition for Class 435.htmTaiPharma Patent Attorney & Attorney at Law, 2005

Delphion .htm


(http://www.moeaipo.gov.tw) (10/31http://www.tipo.gov.tw)

.htm .htm - .htm - ( )-1.htm - ( )5.htm 542722.htmTaiPharma Patent Attorney & Attorney at Law, 2005

(http://www.uspto.gov)United States Patent and Trademark Office Home Page.htm Databases Patent Grant and Patent Application Full-Text and Full-Page Images.htm US Patent Full-Text Database Manual Search.htm Patent Database Search Results ttl-(HCV) and ccl435-$ in 1976 to present.htm United States Patent 6,592,871.htmTaiPharma Patent Attorney & Attorney at Law, 2005

(http://ep.espacenet.com/)

European Patent Office.htm espacenet information.htm


(http://www.jpo.go.jp/) Japan Patent Office.htm Industrial Property Digital Library HOME PAGE.htm Searching PAJ.htm


IBM(http://www.delphion.com/)Delphion Research intellectual property network international and US patent search database.htm Delphion Research intellectual property network international and US patent search database-1.htm Sequences of hepatitis C virus genotypes and their use as prophylactic, therapeutic and diagnostic agents (US6180768).htm


100%-- 3.1



(USPOT) (UPTO) (JPTO)


(Claim) (Specific) (Map)


New) (Non-obviousness) (Useful)


case 1. Amgen V. Chugai GIDNA sequence for EPO ( erythropoietin ) (non-obviousness) Federal Circuit Chugai ( defendant ) ( proving methods ) Amgen ( reasonable expectation of success ) (useful)


Claim 2, as noted above, recites a purified and isolated DNA sequence, and claims 4 and 6 are directed to host cells transformed with such a DNA2, 4, and 6 are not invalid under 35 U.S.C. 103,concluding that the unique probing and screening method employed by Lin in isolating the EPO gene and the extensive effort required to employ that method made the invention nonobvious over the prior art.TaiPharma Patent Attorney & Attorney at Law, 2005

Case 2. In re Patrick and David[8] PATENTS > 16.33 291K16.33 Patent No. 4,376,110 for immunometric assays using monoclonal antibodies was not invalid for obviousness, where patents invention enjoyed immediate commercial success not attributable solely to advertising, led to unexpected advances in no way suggested by scientists use of monoclonal antibodies of different a affinity. 35 U.S.C.A. 103TaiPharma Patent Attorney & Attorney at Law, 2005

file fee) (service fee) (maintain fee)


Literal infringement ( Elements to elements Doctrine of Equivalents (DOE) Estoppel Festo caseTaiPharma Patent Attorney & Attorney at Law, 2005

Genentech vs Eli LillyGenentech developed recombinant DNA technology to produce human insulin Gnentech licensed the technology to Eli Lilly Lilly has since produced a variety of recombinant products including human growth homone HGHand bovine somatotropin BST. Genentech alleges: that production of these products was enabled by use of the licensed Genentech insulin technology. Lilly claims: that Genentechs alleged trade secrets were not trade secrets at all, but were fraudulently or negligently misrepresented as such.TaiPharma Patent Attorney & Attorney at Law, 2005

Assignment () Exclusive Licenses () Non-exclusive License () Joint Venture () Merge & Acquisition ()


Cost Approach Income Approach Market Approach Royalty Base


(confidential agreement) letter of intent) (Contract)TaiPharma Patent Attorney & Attorney at Law, 2005

pharma company Biotech limited Biotech AXXXX Pharma I II ( )A. Biotech ANOXXX B. Biotech Pharma A ( ) TaiPharma Patent Attorney & Attorney at Law, 2005

C.? ? ??

III ( Royalties )A. B. TaiPharma Patent Attorney & Attorney at Law, 2005

C. D.


Biotech wantsIP

Pharma wants


Biotech wants productIP Pharrma wants


Biotech wantspharma (infringement )

Pharma wants

infringement


Biotech wants ( timescale )

Pharma wants


Biotech wants ( expenditure ) ( warranties )

Pharma wants


( improvement & development )Biotech wants improvement TaiPharma Patent Attorney & Attorney at Law, 2005

Pharma wants improvement

Biotech wantsPharma biotch improvement ,

Pharma wants improvents


( termination )Biotech wants A. Pharma A. Biotech

Pharma wants

B. Pharma , B. Biotech TaiPharma Patent Attorney & Attorney at Law, 2005

Biotech wantsC. Pharma

Pharma wantsC. Biotech

D.Biotech D. Biotech


Biotech wants Pharma wants

A. A. Pharma Biotech


Biotech wants

Pharma wants

B. B.Pharma Biotech IPBiotech


Thank you

All Rights Reserved 1


(s.kuznets) 10% (L.Thurow) (Head To Head)(The Future of Capitalism) All Rights Reserved 3

APEC(APEC Technomart -V)19955 19981199911 20019 (TWTM)200111 20011025 20011112156 20021 20002004 10All Rights Reserved 4

From Tangible to Intangible80 70 60 50 40 30 20 10 0 1978 1988 1997 Tangible assets Intangible assets

Source: Joel Goldman, Goldman IP Law, AIPLA Seminar, Apr. 2002 All Rights Reserved 5

Hewlett Packard Intangible80 70 60 50 40 30 20 10 0 1990 2000

Tangible v.

Intangible Assets Tangible Assets

Source: Joel Goldman, Goldman IP Law, AIPLA Seminar, Apr. 2002


Microsoft 400 350 300 250 200 150 100 50 0 1990 2000

Tangible v. Intangible

Intangible Assets Tangible Assets

Source: Joel Goldman, Goldman IP Law, AIPLA Seminar, Apr. 2002 All Rights Reserved 7


()


()


: ( ) :;; ();


() :



()


:-

: : - All Rights Reserved 15

() 156 (35333 23977 7564235) 1. 2.


( )

(0920455312 ) 1. 2. (1) (2)


( )(940202) 1.19-2 2. (1) (2) (3)a. b. 3.: All Rights Reserved 18

( )4. : ; 5. :


( )(940202) 1.19-3 : 2. : 3. : 4. : All Rights Reserved 20

( )5. : 6. : ;


( )7. : 8. : ; 9. : ; All Rights Reserved 22



SWOTAll Rights Reserved 25


( )



= + =

=

=


1





T,B



: 12~15 : 6~82-10

3 Preclinical

1 IND

5-6

Discovery

Clinical Trail :phase :phase phase

2-3 Review & approvalNDA

IND


:

()

2001/ 41 431 42 514/50.9% 270/26.8%

2002/ 56 429 48 533/48.8% 313/28.6%

2003(e)/ 30 463 59 552/46.6% 362/30.5%

225/22.3%

247/22.6%

271/22.9%

1,009/100%

1,093/100%

1,185/100%All Rights Reserved 37

:(2003/09)//IEK-IT IS(2003/11)

A1 A2 A3 A4 A5 A6 319,000,000 228,500,000 125,000,000 200,000,000 300,000,000 75,000,000 1,247,500,000 30,850,000 26,775,000 14,500,000 24,000,000 50,000,000 5,625,000 151,750,000 % 9.7 11.7 11.6 12 16.7 7.5 12.1643


\ ( ( +) )+ +

()

1. 2.

3. 4. 5. 6. 7.

+ + + +

+

+

8. 9.

-

+

10. 11. 12.

+ +

+12 + 4


\ 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12.

()

34610 15711 28912



2004






ICIC

IC


(1) (2) (3) (4)

(1) (2)

(1) (2)

(3) (3) (4)(4) (5) All Rights Reserved 48

(5) (5) (6)

1. 30%

2.

3.

4. All Rights Reserved 49

X Y1Y2X Y1 Y2 All Rights Reserved 50

Ufi X

Y1 Y2 /


()MV = UFi i I =1 (i + R )N

+ UFj j j = N +1 (1 + r )

M

1. N=10~17 2. N=2~3 1. N=1.5~2 2. N=5~15

1. Dram N=1.5~2 2. IC N=1.5 1. N=1~2 2. N=3~5 3. N=7~8 N=1~2

1. M=5 2. M=2~3 1. M=2~3 2. M= 0 1. Dram M=2~4 2. IC M=1~2 1. M=1~2 2. M=3~5 3. M=10 M=2~3


= +

=

=

=


( )


Licensed TargetSIP Stack SIP API IP Phone SIP Call Control IP Phone Application Software CMB

RTP Jitter Handler

Audio Frame Handler

Packer Buffer

Voice Codec

Message Handler

Middleware API

IP Phone SIP Media Control

Middleware SoftwareAll Rights Reserved 55

:

G.729 Patent BriefingDefinitions 1.G.729the audio compression standard of the ITU.Coding of Speech at 8 kbit/s using CS-ACELP 2.G.729 Annex AReduced Complexity 8 kbit/s CS-ACELP Speech Codec. 3.G.729 Annex BA silence compression scheme for G.729 optimized for terminals conforming to ITU_T V.70 4. G.729 Annex CReference Floating-Point Implementation for G.729 CS-AcELP 8 kbit/s Speech Coding. 5. G.729 Annex D6.4 kbit/s CS-ACELP Speech Coding algorithm. 6. G.729 Annex E11.8 kbit/s CS-ACELP Speech Coding algorithm.

:


G.729A/B Patent Holders

ITU-T G.729 ITU-T G.729 (France Telecom) Universite de Sherbrooke (NTT)19983 G.729Sipro Lab Telecom Sipro 50 G.729 :

G.729 9 5 4 4 3 3 2 2 2 2 1 1 1 1 1

Nippon Telegraph and Yelephone Corporation Universite de Sherbrooke France Telecome/France Telecome Research and Development Center NEC Corporation Fufitsu Ltd. Lucent Technologies Inc. AT&T Corp. Mindspeed Technologies Inc. Mitsubishi Electric Corp. Simens

BTG USA Inc Centro Study Laboratory Telecommunication SPA Hughes Electronicis Corporation Koninklijke N.V.(Royal KPN N.V.) Nokia Robert Bosch GmbH

All Rights Reserved 1 57

SIPRO LAB TELECOM1. 2. 3. 4.

5.

Founded in 1994 Canadian Company and based in Quebec,Montreal Positionas the Patent License Administrator(LA) Representing Universite de Sherbrooke France Telecom Mitsubishi Electric Corporation Nippon Telegraph and Telephone Corporation Web Sitehttp//www.sipro.com

:


Sipro LicenseOption 1-Royalty BasedInitial Fee$15,000 Royalty Cap -Manufacturers of end products$1.807M or -Chipsets for 5.496M Minumum Annual Royalty (after first year)$7,500

Number of Channels 10M

Royalty Fee $1.38 $1.20 $0.96 $0.78 $0.66 $0.54 $0.30

Accumulate to Cap(USD$) 138,000 480,000 480,000 709,000/1,560,000 (up tp 1,908,975 channels sold) 1,320,000 1,518,000/2,700,000 (up to 7,8111,112 channel sold)All Rights Reserved 59

:

Sipro LicenseOption 2-Pre-paidMaximum number of channels sold Pre-paid license fee G.729Annex A+Annex B Pre-paid unit(channel)* royalty G.729A+BMaximum number of channels sold50,000-100k 100K-200K 200K-500K 200K-1M 200K-3M 200K-5M 200K-10M 200K-15M 500K-1M 500K-3M

Upgrade fee to be paid G729 Annex A$63,180 $102,780 $270K $602K $1,667M $2,490M $3,366M $4,165M $336K $1,361M $2,152M $2,989M $3,752M $1,014K $1,772M $2,573M $3,298M $792K $1,554M $2,242M $826K

50,000 100K 200K 500K 1M 3M 5M 10M 15M

$67,860 $120,120 $206K $445K $725K $1,606M $2,197M $2,748M $3,498M

$1.36 $1.20 $1.03 $0.89 $0.72 $0.54 $0.44 $0.28 $0.23

500K-5M 500K-10M 500K-15M 1M-3M 1M-5M 1M-10M 1M-15M 3M-5M 3M-10M

*Corresponding per unit royalty in the pre-paid fee licensing scheme.Not available on a per unit basis.

3M-15M 5M-10M 5M-15M 10M-15M

:

All Rights Reserved $1,475M 60 $924K

Sipro LicenseOption 3-Fully Paid-up

For manufactures of end-products$1.116M For chipsets manufacturers$3.498M

:


CCL Pass-Through model Middleware module Sipro

G.729A/B pass-through Sipro pre-paid price 1. Sipro2. 3.Sipro : All Rights Reserved 62

Proposed License FeeCCL Pass-ThroughMax. Channels sold 40,000 Pre-paid License 44,608 Per Unit 1.115

Comparison---Qty:100K Sipro Royalty Based:153,000 Initial Fee:15,000+Royaty:138,000 Sipro Pre-paid Option: (A)120,120 (B)67,860+63,180=131,040 CCL Pass-Through Option: 44,608+56,400=101,008

Upgrade FeeMax. Channels sold 40K-100K 100K-200K 200K-600K Qty 60,000 100,000 400,000 Upgrade Fee 56,400 70,500 231,240 Per Unit 0.94 0.71 0.58 Sipro Royalty 153,000 100.00% Sipro Prepaid(A) 120,120 78.51% Sipro Prepaid(B) 131,040 85.65% CCL Passthru 101,008 66.02%

:


G.729 A/B Patent License Acquired ScheduleLicensees Approaching Stage Negotiation Stage Preparation Stage Dec/04 License term Discussion 2004/Dec 2005Customer Requirement Bulid-up

G.729A/B Patent License acquired

VoIP Phone Customer visit

Target time to license By end of April 05

Jan

Feb

Mar

Apr

May

Jun

July

Aug

:


() All Rights Reserved 65

() All Rights Reserved 66


Documents

生技產業分析